Our thoughts go out to those affected by Hurricane Sandy as many continue to face challenges due to extensive storm damage and disruptions to basic services.
To support Hurricane Sandy disaster relief efforts, The Merck Company Foundation has donated $250,000 to the American Red Cross on top of its initial $500,000 donation earlier this year to the American Red Cross Annual Disaster Giving Program.
In addition, through the Merck Medical Outreach Program, Merck has donated medicines, vaccines and consumer care products to its partners to assist with disaster response efforts. Merck has also pledged $150,000 to Save the Children's "Hurricane Sandy Emergency Fund" in support of its Journey for Hope program designed to help children develop coping mechanisms during a disaster. Funding support to the disaster recovery efforts of Americares and Direct Relief International was also granted.
We are engaged in discussions with a number of other international, national and local agencies to determine their needs and are committed to providing additional financial support as their needs evolve over the coming weeks and months.
Visit our Facebook page to share how you're helping support disaster relief efforts.
Learn more about Merck's ongoing support of disaster relief efforts.
Copyright. © 2009-2016 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved.
This website of Merck & Co., Inc., Kenilworth, NJ, USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation in the United States and internationally; global trends toward healthcare cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.